Poolbeg Pharma plc – POLB 001 patent granted in South Africa for the treatment or prevention of hypercytokinemia and severe influenza
Patent decision strengthens Poolbeg’s intellectual property portfolio 30 June 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces it has received notification of the official decision to grant Poolbeg’s Immunomodulator II patent in South Africa, providing protection for POLB 001 for the prevention of hypercytokinaemia and […]
